194 related articles for article (PubMed ID: 17768093)
1. Role of the nurse in preserving patients' independence.
Maxwell C
Eur J Oncol Nurs; 2007; 11 Suppl 2():S38-41. PubMed ID: 17768093
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate therapy for metastatic bone disease: the pivotal role of nurses in patient education.
Fitch MI; Maxwell C
Oncol Nurs Forum; 2008 Jul; 35(4):709-13. PubMed ID: 18591175
[TBL] [Abstract][Full Text] [Related]
3. The role of nurses in preserving patients' functional independence: Zoledronic acid--evidence and experience in metastatic bone disease.
Fitch MI
Eur J Oncol Nurs; 2007; 11 Suppl 2():S27. PubMed ID: 17804295
[No Abstract] [Full Text] [Related]
4. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
5. [The role of oncology nurses in treatment outcomes. What can we do for the patients' compliance treated with intravenous zoledronic acid?].
Zatkóné Puskás G
Magy Onkol; 2009 Jun; 53(2):145-8. PubMed ID: 19581180
[TBL] [Abstract][Full Text] [Related]
6. Burden of bone disease.
Kinnane N
Eur J Oncol Nurs; 2007; 11 Suppl 2():S28-31. PubMed ID: 17768092
[TBL] [Abstract][Full Text] [Related]
7. Management of bisphosphonate treatment in clinical practice.
Aapro MS
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S28-32. PubMed ID: 18068488
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates: clinical experience.
Coleman RE
Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
[TBL] [Abstract][Full Text] [Related]
11. On the horizon: can bisphosphonates prevent bone metastases?
Coleman R
Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for zoledronic acid treatment of patients with bone metastases.
Berenson JR
Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
Rosen LS
Semin Oncol; 2002 Dec; 29(6 Suppl 21):28-32. PubMed ID: 12584692
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
Costa L
Breast; 2007 Dec; 16 Suppl 3():S16-20. PubMed ID: 18032044
[TBL] [Abstract][Full Text] [Related]
15. The use of bisphosphonates in cancer patients.
Wu S; Dahut WL; Gulley JL
Acta Oncol; 2007; 46(5):581-91. PubMed ID: 17562434
[TBL] [Abstract][Full Text] [Related]
16. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease.
Saad F; Lipton A
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S17-23. PubMed ID: 18068486
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer: bisphosphonate therapy for metastatic bone disease.
Body JJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
[TBL] [Abstract][Full Text] [Related]
18. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer.
Clemons M; Dranitsaris G; Cole D; Gainford MC
Oncologist; 2006 Mar; 11(3):227-33. PubMed ID: 16549806
[TBL] [Abstract][Full Text] [Related]
19. [Current use of bisphosphonates in clinical oncology].
Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
[TBL] [Abstract][Full Text] [Related]
20. Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer.
Hirsh V
Clin Lung Cancer; 2009 Jul; 10(4):223-9. PubMed ID: 19632938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
